ZCM
CHRS icon

Zebra Capital Management’s Coherus Oncology CHRS Stock Holding History

Zebra Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,707
Closed -$122K – 70
2022
Q3 		$122K Buy
12,707
+137
+1% +$1.39K 0.46% 66
2022
Q2 		$91K Sell
12,570
-369
-3% -$3.21K 0.27% 90
2022
Q1 		$167K Sell
12,939
-3,807
-23% -$48.4K 0.38% 100
2021
Q4 		$267K Sell
16,746
-6,172
-27% -$108K 0.43% 85
2021
Q3 		$368K Buy
+22,918
New +$336K 0.45% 81

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Zebra Capital Management's CHRS Position: Q4 2022 in Review

Zebra Capital Management sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 12,707 shares — an estimated $122K sold.

Zebra Capital Management first reported a position in CHRS in Q3 2021 and held it in 5 quarters. The position peaked at $368K in Q3 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Zebra Capital Management reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Zebra Capital Management sold 12,707 Coherus Oncology shares in Q4 2022, an estimated $122K.
  • Zebra Capital Management first reported a position in Coherus Oncology in Q3 2021 and held it in 5 quarters.
  • Zebra Capital Management's Coherus Oncology position peaked at $368K in Q3 2021.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Zebra Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.